Who is sponsoring NCT01275105?

NCT01275105 is sponsored by Eye Therapies, LLC.

What condition does NCT01275105 study?

NCT01275105 studies Allergic Conjunctivitis.

What drugs are being tested in NCT01275105?

Interventions: Vehicle, Brimonidine Tartrate 0.01%, Brimonidine Tartrate 0.025%, Oxymetazoline HCl 0.025%.

What is the status of NCT01275105?

NCT01275105 is currently COMPLETED.

Last reviewed 2012-03-02 · How we verify

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

NCT01275105 Phase 2 COMPLETED

The purpose of this study is to evaluate the safety, efficacy, and dose response of brimonidine tartrate ophthalmic solution as compared to placebo in the prevention of allergen-induced conjunctival redness using a conjunctival allergen challenge (CAC) model. It is hypothesized that low-dose brimonidine tartrate ophthalmic solution will be more effective than vehicle in the prevention of conjunctival redness induced by conjunctival allergen challenge when instilled prior to the allergen challenge.

Details

Lead sponsor	Eye Therapies, LLC
Phase	Phase 2
Status	COMPLETED
Enrolment	68
Start date	2011-01
Completion	2011-03

Conditions

Allergic Conjunctivitis

Interventions

Vehicle
Brimonidine Tartrate 0.01%
Brimonidine Tartrate 0.025%
Oxymetazoline HCl 0.025%

Primary outcomes

Conjunctival Redness — at specified timepoints for up to 30 minutes

Countries

United States